Stockreport

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide...

Hoth Therapeutics, Inc.  (HOTH) 
PDF Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Ppara (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity NEW [Read more]